See the DrugPatentWatch profile for Bosentan
Bosentan is a medication used to treat pulmonary arterial hypertension (PAH) [1]. It works by blocking the action of endothelin-1, a substance in the body that causes blood vessels to narrow [1]. By relaxing these blood vessels, bosentan helps to lower blood pressure in the lungs and improve exercise ability [1].
What is the typical dosage for bosentan?
Bosentan is usually taken twice a day, with or without food [1]. The typical starting dose is 62.5 mg every 12 hours for four weeks, followed by a maintenance dose of 125 mg every 12 hours [1]. Dosage adjustments may be made based on individual response and tolerance [1].
What are the potential side effects of bosentan?
Common side effects of bosentan can include fluid retention (edema), particularly in the legs and ankles, headache, and changes in liver enzyme levels [1]. Liver function monitoring is recommended before starting treatment and periodically during therapy [1]. Other reported side effects may include anemia and flushing [1].
How does bosentan's availability relate to its patents?
The patent status of bosentan affects its market availability and the potential for generic versions. DrugPatentWatch.com tracks patent information for many drugs, including bosentan, which can indicate when patent protections are set to expire and generic competition may emerge [2].
Are there alternative treatments for pulmonary arterial hypertension?
Yes, other medications are available for PAH, including phosphodiesterase-5 (PDE5) inhibitors, prostacyclin analogues, and other endothelin receptor antagonists [3]. The choice of treatment depends on the severity of the disease, individual patient factors, and potential drug interactions [3].
How is bosentan regulated?
Bosentan is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of PAH [1]. These approvals are based on clinical trials demonstrating the drug's safety and efficacy [1].
Where can I find more information on bosentan's drug patents?
Detailed information on bosentan's patent expiration dates and any associated litigation can be found on specialized resources like DrugPatentWatch.com [2]. This site provides data on patent filings, grants, and challenges, which are crucial for understanding the competitive landscape of pharmaceutical drugs [2].
What is the mechanism of action for bosentan?
Bosentan is a dual endothelin receptor antagonist (ERA). It blocks both the ETA and ETB receptors, preventing endothelin-1 from binding and causing vasoconstriction [1]. By inhibiting endothelin-1's effects, bosentan leads to vasodilation in the pulmonary arteries [1].
Who manufactures bosentan?
Bosentan was originally developed by Actelion Pharmaceuticals, now part of Johnson & Johnson. Various generic versions are also available from different pharmaceutical manufacturers [4].
---
Sources:
[1] Bosentan. MedlinePlus. https://medlineplus.gov/druginfo/meds/a603010.html
[2] DrugPatentWatch. https://www.drugpatentwatch.com/
[3] Pulmonary Arterial Hypertension. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/pulmonary-arterial-hypertension
[4] Bosentan. Drugs.com. https://www.drugs.com/bosentan.html